31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Amyloid-beta (Aβ) accumulation was evaluated with 2 [(11)C]Pittsburgh compound B (PiB) positron emission tomography scans about 2.5 years apart in 146 cognitively normal adults. 3 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
In contrast, the cerebrovascular resistance index was significantly elevated in amyloid-positive versus amyloid-negative cases, with additional elevation in patients with Alzheimer's disease. 3 key findings →
Participants: 232 Evidence: low
Full summary, score breakdown and related studies → Original source
In this cross-sectional study, we found an association between Aβ brain burden measured in vivo and DBP and cortisol, indicating a possible link between these CVRF and Aβ burden measured by PiB-PET. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Retinal vessel density was higher in individuals with preclinical AD. 3 key findings →
Participants: 124 Evidence: low
Full summary, score breakdown and related studies → Original source
In this study we compared Pittsburgh compound-B (PIB) positron emission tomography (PET) amyloid imaging, fluorodeoxyglucose PET for metabolism, and magnetic resonance imaging (MRI) for structure to predict conversion from amnestic mild cognitive impairment (MCI) to Alzheimer's dementia using data from the Alzheimer's Disease Neuroimaging Initiative cohort. 5 key findings →
Participants: 29 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Frontotemporal dementia (FTD) and Alzheimer's disease are sometimes difficult to differentiate clinically because of overlapping symptoms. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Atrophy patterns on MRI can reliably predict three neuropathological subtypes of Alzheimer's disease (AD): typical, limbic-predominant, or hippocampal-sparing. 5 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
In middle-aged community participants, we observed a significant inverse association of anthropometric and CT-based measurements of abdominal, especially visceral, fat with total brain volume. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Pick disease tau neuropathology may originate in limbic/paralimbic cortices. 2 key findings →
Participants: 21 Evidence: moderate
Full summary, score breakdown and related studies → Original source
These results support a biphasic model of changes in AD, which could affect the selection of patients for clinical trials and the use of magnetic resonance imaging as a surrogate marker of disease modification. 2 key findings →
Participants: 254 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders, and are characterized by deposition of specific proteins in the brain. 2 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Compared with healthy subjects, patients with AD showed a significant reduction in choroidal thickness. 3 key findings →
Design: cross-sectional Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
Retinal blood flow in MCI is intermediate between what is measured in control subjects and in AD patients. 4 key findings →
Participants: 52 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is one of the most common causes of dementia in the world. 5 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research suggests that diet may play a role in AD, but it is inconclusive relative to which dietary approach provides the most neuroprotective effects. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects 50 million people worldwide, with 10 million new cases occurring each year. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
These data confirm the challenges of correctly diagnosing AD without using biomarkers. 2 key findings →
Participants: 2,052 Evidence: low
Full summary, score breakdown and related studies → Original source
In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid therapies for Alzheimer's disease (AD) modestly slow cognitive decline but carry significant risk of amyloid-related imaging abnormalities (ARIAs), brain swelling, and hemorrhage, particularly in apolipoprotein E ε4 carriers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
AI-derived MRI markers, particularly GM volume and MH burden, provide valuable predictors of cognitive response and ARIA risk in patients treated with lecanemab. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lecanemab's binding target is similar to other antibodies'. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The global burden of Alzheimer's disease (AD) is accelerating, with U.S. prevalence projected to reach nearly 13 million by 2060. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid monoclonal antibodies such as lecanemab are increasingly used to treat Alzheimer's disease (AD) and are associated with amyloid-related imaging abnormalities (ARIA), including hemorrhagic findings (ARIA-H). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Baseline global Centiloid was not independently associated with ARIA in patients treated with lecanemab. 5 key findings →
Participants: 41 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events